NCT06287684 Molecular Subtype-Specific Mechanisms and Therapeutic Strategies in Sepsis
| NCT ID | NCT06287684 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Mater Dei Hospital, Malta |
| Condition | Sepsis |
| Study Type | OBSERVATIONAL |
| Enrollment | 460 participants |
| Start Date | 2023-09-13 |
| Primary Completion | 2028-12-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 460 participants in total. It began in 2023-09-13 with a primary completion date of 2028-12-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Sepsis is a complex syndrome that causes lethal organ dysfunction due to an abnormal host response to infection. No drug specifically targeting sepsis has been approved. The heterogeneity in sepsis pathophysiology hinders the identification of patients who would benefit, or be harmed, from specific therapeutic interventions. Recent clinical genomics studies have shown that sepsis patients can be stratified as molecular subtypes, or subclasses, with clinical implications. Classifying sepsis patients as molecular subtypes revealed that a poor prognosis subtype was characterized by immunosuppression and septic shock. Therefore, it has become essential to identify patients who may benefit from or be adversely affected by specific treatments, thereby identifying bona fide treatable traits or endotypes. The goal of this study is to assist the physician at the bedside in tailoring the treatment of an individual patient suffering from sepsis by generating rapid molecular information about immune status.
Eligibility Criteria
Inclusion criteria: * Age ≥ 18 years * Consent card signed Exclusion criteria: * Consent card not signed * Pregnancy * Prisoners * Elective cardiac surgery patients with an uncomplicated stay.
Contact & Investigator
Frequently Asked Questions
Who can join the NCT06287684 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Sepsis. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06287684 currently recruiting?
Yes, NCT06287684 is actively recruiting participants. Contact the research team at brendon.scicluna@um.edu.mt for enrollment information.
Where is the NCT06287684 trial being conducted?
This trial is being conducted at Msida, Malta.
Who is sponsoring the NCT06287684 clinical trial?
NCT06287684 is sponsored by Mater Dei Hospital, Malta. The trial plans to enroll 460 participants.